Ms Continmorphine

According to the FDA label: Opium tincture is useful for the treatment of diarrhea.

119,608 adverse event reports submitted to the FDA (1999–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Ms Contin in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Ms Contin adverse event reports by reporter sex
SexReports
Female47,408
Male42,994
Unknown253

By Age Group

View age group data as a table
Ms Contin adverse event reports by reporter age group
Age groupReports
0-171,353
18-343,867
35-498,202
50-6414,326
65-748,532
75+5,946

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Ms Contin. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Ms Contin adverse event reports by reported outcome
OutcomeReports
Other Serious65,939
Death34,624
Hospitalization22,688
Non-Serious17,141
Disability9,093
Life-Threatening3,321

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Ms Contin. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Ms Contin adverse event reports by year
YearReports
19993
20032
20041,657
20051,526
20061,241
2007791
2008884
2009957
20101,280
20111,570
20122,358
20131,882
20142,319
20153,026
20163,584
20174,918
201826,845
20194,810
20208,656
202120,577
202214,401
20238,462
20243,687
20253,455
2026 (partial)717

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Ms Contin

In FDA adverse event reports that mention Ms Contin, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026